Want to see HK:6877 full AI Analyst Report?
Top Page
CLSA Premium Ltd.
(6877)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$0.10
▼(-34.00% Downside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by ongoing losses and meaningfully negative operating/free cash flow despite a strong, debt-free balance sheet. Technicals are mildly positive in the short term but remain below longer-term moving averages, while valuation is unattractive given the negative P/E and lack of dividend data.
Positive Factors
Revenue rebound and gross-margin expansion
The sharp revenue rebound indicates improving business activity, while the substantial gross-margin improvement suggests better pricing, mix, or cost control. If sustained, these gains can strengthen operating leverage and provide a stronger foundation for restoring profitability over the next several quarters.
Negative Factors
Persistent operating and net losses
Revenue and gross margin improvements have not yet translated into positive operating or net earnings. Continued losses reduce the company’s ability to compound capital internally, weaken returns on its substantial equity base, and indicate that further execution is needed before profitability can be considered durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound and gross-margin expansion
The sharp revenue rebound indicates improving business activity, while the substantial gross-margin improvement suggests better pricing, mix, or cost control. If sustained, these gains can strengthen operating leverage and provide a stronger foundation for restoring profitability over the next several quarters.
Read all positive factors
CLSA Premium Ltd. (6877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$201.30M
Dividend Yield1.42%
Average Volume (3M)137.50K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth59.21%
EPS Growth-221.43%
CountryHK
Employees15
SectorFinancial
Sector Strength70
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,033,290,000
10 Day Avg. Volume95,500
30 Day Avg. Volume137,500
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.24
Price to Sales (P/S)2.72
P/FCF Ratio-437.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CLSA Premium Ltd. Business Overview & Revenue Model
Company Description
Engaged in the distribution of health-related goods and services, Top Eminent Healthcare Group Limited operates as an investment holding company, with its activities spanning Australia, Hong Kong, and New Zealand....
CLSA Premium Ltd. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
82
Very Positive
Cash Flow
36
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 177.34M | 109.83M | 86.49M | 191.17M | 39.13M | 5.44M |
| Gross Profit | 127.61M | 40.59M | 28.26M | 34.55M | 4.37M | -13.02M |
| EBITDA | -2.90M | -6.50M | -2.54M | 6.97M | -8.17M | -37.05M |
| Net Income | -5.29M | -7.11M | 11.34M | 9.84M | -31.05M | -56.54M |
Balance Sheet | ||||||
| Total Assets | 275.21M | 246.44M | 279.38M | 251.78M | 284.31M | 330.62M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 207.75M | 205.17M | 222.39M | 211.79M | 234.47M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.64M |
| Total Liabilities | 32.41M | 5.76M | 35.08M | 11.91M | 53.51M | 61.86M |
| Stockholders Equity | 242.80M | 240.68M | 244.31M | 239.87M | 230.80M | 268.76M |
Cash Flow | ||||||
| Free Cash Flow | -15.13M | -683.00K | -19.90M | 1.82M | -16.79M | -40.12M |
| Operating Cash Flow | -15.13M | -656.00K | -19.90M | 1.82M | -16.79M | -39.26M |
| Investing Cash Flow | 3.80M | -27.00K | 9.48M | 9.64M | 1.78M | 2.21M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | -1.00K | -2.12M | -10.14M |
CLSA Premium Ltd. Technical Analysis
Neutral
0.15
Price Trends
0.10
Positive
0.11
Negative
0.13
Negative
Market Momentum
<0.01
Negative
59.61
Neutral
46.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6877, the sentiment is Neutral. The current price of 0.15 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.13, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.61 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6877.
CLSA Premium Ltd. Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$465.12M | 3.58 | 3.57% | 9.43% | -22.54% | 60.00% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
64 Neutral | HK$384.41M | 4.33 | 57.05% | 12.16% | 280.60% | 330.73% | |
62 Neutral | HK$341.80M | 5.92 | 8.47% | 7.20% | 99.18% | 272.34% | |
58 Neutral | HK$169.67M | 79.43 | 3.39% | 1.86% | 5.88% | ― | |
51 Neutral | HK$201.30M | -55.00 | -2.19% | 1.42% | 59.21% | -221.43% | |
45 Neutral | HK$204.81M | -4.91 | -23.72% | 1.72% | 10.05% | -40.15% |
* Financial Sector Average
HK:6877
CLSA Premium Ltd.
0.10
-0.13
-56.96%
HK:0510
CASH Financial Services Group
0.46
-0.06
-11.54%
HK:0717
Emperor Capital Group Limited
0.07
-0.03
-28.57%
HK:1073
Da Yu Financial Holdings Limited
0.10
-0.04
-28.06%
HK:8350
Excalibur Global Financial Holdings Limited
0.41
0.24
145.51%
HK:8439
Somerley Capital Holdings Ltd
1.08
0.72
201.12%
CLSA Premium Ltd. Corporate Events
Top Eminent Healthcare Returns to Profit on Strong Healthcare Product Sales
Aug 17, 2026
Top Eminent Healthcare Group Limited reported a 64.9% jump in total income to HK$74.5 million for the six months ended 30 June 2026, driven by a 70.5% surge in revenue from its healthcare products business to HK$70.9 million. The company maintaine...
Top Eminent Healthcare Schedules Board Meeting to Approve Interim Results
Jul 31, 2026
Top Eminent Healthcare Group Limited announced that its board will convene a meeting on 17 August 2026 to approve and publish the interim results for the six months ended 30 June 2026. The board will also consider the declaration of an interim div...
Top Eminent Healthcare Signals Profit Turnaround Amid Ongoing Litigation
Jul 17, 2026
Top Eminent Healthcare Group Limited has signalled a return to profitability for the six months ended 30 June 2026, with an expected consolidated net profit of about HK$1 million versus a HK$2.2 million loss a year earlier. Management attributes t...
Top Eminent Healthcare reshapes board with new executive director
Jun 26, 2026
Top Eminent Healthcare Group Limited announced that non-executive director Li Jiong will step down from the board on 30 June 2026 due to other business commitments, with the company noting there is no disagreement or outstanding claims related to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.